InstalabLoading...
InstalabLoading...
Your gut is home to trillions of bacteria, and a single phylum called Bacteroidetes accounts for a large share of them. The amount of Bacteroidetes in your stool reflects how your gut community is currently structured, which in turn connects to digestion, immune signaling, and how your body handles sugar, fat, and inflammation.
Measuring Bacteroidetes will not give you a yes-or-no diagnosis. It is a research-grade window into one of the most studied bacterial groups in the human body, and it is most useful when tracked over time alongside other gut markers as you change your diet, lifestyle, or medications.
Bacteroidetes (now often called Bacteroidota) is a phylum of gram-negative bacteria, meaning a wide family of microbes grouped by shared cell-wall features. The genus Bacteroides is its best-known member. These bacteria specialize in breaking down complex carbohydrates and host-derived sugars in the colon, producing short-chain fatty acids that feed gut cells and influence immune balance.
Specific Bacteroides species can encourage regulatory immune cells (the kind that calm inflammation) and produce bioactive lipids studied for effects on glucose metabolism and blood vessel health. They are usually framed as part of a healthy adult gut, but their role depends heavily on context, the rest of the community, and which species dominate.
You may have seen the Firmicutes-to-Bacteroidetes ratio (F/B ratio) marketed as a single number that captures gut health or obesity risk. The actual evidence is much messier. A large review concluded that the F/B ratio is not a reliable obesity biomarker because results vary widely between studies and are heavily shaped by diet, geography, and how the lab processes samples.
In adults, some studies show higher Firmicutes and lower Bacteroidetes with obesity, others show the opposite, and meta-analyses describe the picture as highly heterogeneous. In children, lower Bacteroidetes and lower Bacteroides or Prevotella levels have been linked with higher BMI (a basic measure of weight relative to height) and obesity risk. The takeaway: do not stake your decisions on a single ratio.
Bacteroidetes is most consistently informative at the species level rather than the phylum level. In ulcerative colitis (a form of inflammatory bowel disease), several key Bacteroidetes species drop in active disease, and the cumulative loss of these species correlates strongly with worse endoscopic disease activity in 86 patients. These species express genes linked to immune regulation, which fits with their disappearance during flares.
In a study of 1,914 Chinese adults, higher levels of the genus Bacteroides were associated with lower BMI, lower waistline measurements, and lower LDL cholesterol (the heart-disease-driving form of cholesterol). In nonalcoholic fatty liver disease, the F/B ratio tracks with steatosis (fat buildup in the liver) and obesity, while a different phylum, Proteobacteria, correlates more strongly with fibrosis (scarring).
In end-stage kidney disease patients on hemodialysis, lower Bacteroides was seen in those who later died from cardiovascular causes, a hint that low levels can track with worse outcomes in this group. A breast cancer study found the F/B ratio in serum extracellular vesicles (tiny membrane-bound packets bacteria release into the blood) was about three times lower in patients than controls, with higher Bacteroides linked to higher fasting glucose.
More Bacteroidetes is not always better. A Mendelian randomization analysis (a genetic study design that uses inherited variants to suggest cause and effect) of 282,477 people found that higher genetically predicted Bacteroidetes abundance may increase the risk of type 1 diabetes. A separate genetic analysis of 18,340 people linked the Bacteroidia class to lower eGFR (a measure of how well your kidneys filter blood).
This is where Bacteroidetes stops behaving like a simple good-or-bad marker. Different species and different community structures interact with different organ systems in different ways. A pattern that looks protective for one disease can look harmful for another, which is why a single number, on its own, cannot tell you whether your gut is in a good place.
In a study of 90 young adults, higher Bacteroidetes was reported in people with major depressive disorder. A meta-analysis of gut microbiome data also found higher Bacteroidetes in people with mild cognitive impairment, an early stage of cognitive decline that can precede Alzheimer's disease. These findings are associations, not proof of cause, and show how context-specific gut signals can be.
There are no consensus clinical cutpoints for Bacteroidetes. Reported relative abundances vary enormously even in healthy people: across 728 healthy subjects in pooled studies, Bacteroidetes ranged from 0.6% to 86.6% of total gut bacteria. In rigorously screened healthy Chilean volunteers, it ranged from 4% to 64% despite controlled diet, anthropometric, and inflammatory marker entry criteria.
These figures come from research cohorts using different sequencing methods and processing pipelines, and they describe a population where wide variation is normal. They are illustrative orientation, not a target to hit. Your own lab will report its own quantification, and meaningful comparisons should be made within the same lab and method, not against an absolute number.
| Population | Reported Range (Relative Abundance) | What It Suggests |
|---|---|---|
| Pooled healthy adults across studies (n=728) | 0.6% to 86.6% | Extremely wide variation in 'healthy' people; a single value sits inside a noisy distribution. |
| Screened healthy Chilean volunteers | 4% to 64% | Even with strict health criteria, individual variation remains substantial. |
| Healthy adults, separate cohort | Firmicutes 25% to 67%, Bacteroidetes within wide range | The ratio between dominant phyla varies by person, diet, and methodology. |
Source: Magne et al., Nutrients 2020 (review summarizing values across studies including Fujio-Vejar et al., 2017).
Bacteroidetes is not a higher-is-better or lower-is-better marker. Different studies find that lower levels track with worse ulcerative colitis, lower Bacteroides tracks with cardiovascular death in dialysis patients, while genetic studies suggest higher Bacteroidetes may worsen type 1 diabetes risk and kidney function. The framework that resolves this: Bacteroidetes is a phenotype indicator, not a disease score. Different community configurations carry different risks for different organ systems, and the same phylum-level number can reflect very different underlying biology depending on which species dominate and what else is going on in the gut.
A single Bacteroidetes value sits inside an enormous normal range and is heavily influenced by what you ate that week, recent antibiotic exposure, and even how the lab processed your sample. Detecting a real change in your gut composition requires repeated measurements under similar conditions, ideally at the same lab using the same method, before drawing conclusions.
A reasonable rhythm: get a baseline. If you are changing your diet, starting a probiotic or prebiotic, or beginning a medication known to shift the gut (like metformin or statins), retest in 3 to 6 months to see whether the change moved your community. After that, annual checks are enough to catch drift over time. Looking at the trend, and at companion markers, is more meaningful than fixating on one snapshot.
Bacteroidetes is unusually sensitive to short-term and methodological factors. Lead with that when interpreting your number.
Some commonly used drugs also incidentally shift Bacteroidetes-related taxa without necessarily causing gut disease: PPIs (proton pump inhibitors, used for reflux), laxatives (which can raise Alistipes and Bacteroides species), and oral corticosteroids and levothyroxine (a thyroid hormone replacement) have all been linked to changes in gut composition or diversity in large population data. If you are on these, your result reflects your current pharmacology as much as your underlying biology.
An unusual Bacteroidetes value alone is rarely a call to action. The more useful question is what pattern surrounds it. If your Bacteroidetes is low alongside loss of butyrate-producing species, low microbial diversity, and elevated calprotectin (a stool inflammation marker), that combination is worth investigating with a gastroenterologist, especially if you have gut symptoms. If your Bacteroidetes is unusual but other markers look fine and you feel well, the most useful next step is a repeat test in 3 to 6 months under similar conditions.
Companion stool tests that add context include calprotectin and pancreatic elastase (digestive enzyme output), short-chain fatty acid quantification, and broader microbiome panels that look at species-level signatures rather than the phylum alone. If you have a known condition like ulcerative colitis, dialysis-dependent kidney disease, or type 1 diabetes risk, share your microbiome results with the specialist already managing that condition; the interpretation differs sharply by disease.
Evidence-backed interventions that affect your Bacteroidetes level
Bacteroidetes is best interpreted alongside these tests.